Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanobiotix SA

www.nanobiotix.com

Latest From Nanobiotix SA

Nanobiotix CEO: Curadigm Spin-Out Platform Could ‘Redefine’ Drug-Body Balance

Laurent Levy tells Scrip Nanobiotix’s freshly-created subsidiary Curadigm aims to improve bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.

Companies Drug Delivery

Nanobiotix's Hensify Earns CE Mark For Soft-Tissue Sarcoma

The CE mark will make Hensify nanoparticle radioenhancers available in 27 European countries. Hensify is the brand name for NBTXR3, an aqueous suspension of crystalline hafnium oxide nanoparticles, approved specifically for treating locally advanced soft-tissue sarcoma.

Research & Development Approvals

Tech Transfer Roundup: GE Healthcare, Vanderbilt Partner To Optimize Precision Cancer Immunotherapy

Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.

Deals Commercial

Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom

Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Nanobiotix SA
  • Senior Management
  • Patrick Tricoli, PharmD, CEO & Global Head, Bus. Dev.
    Philippe Mauberna, CFO
    Edwina Baskin-Bey, MD, CMO
    Brandon Owens, VP, Strategic Mktg. & Corp. Communications
  • Contact Info
  • Nanobiotix SA
    Phone: (33) 1 40 26 04 70
    60 rue de Wattignies
    Bldg. B
    Paris, 75012
    France
UsernamePublicRestriction

Register